Seattle Genetics, GSK in Next-Generation Antibody Deal

Seattle Genetics' third deal in two months signals big pharma's growing interest in antibody conjugate technology or "empowered" antibodies for immunotherapies targeting cancer and other hard-to-treat diseases.